Related Experiment Video

Updated: May 26, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Management of treatment-emergent peripheral neuropathy in multiple myeloma

P G Richardson1, M Delforge, M Beksac

  • 1Dana-Farber Cancer Institute, Boston, MA 02115, USA. paul_richardson@dfci.harvard.edu

Leukemia
|December 24, 2011
PubMed

Insights

Peripheral neuropathy (PN) is a significant complication in multiple myeloma (MM) treatment. Effective management strategies, including monitoring and dose adjustments, are crucial for minimizing PN incidence and severity during MM therapy.

Area of Science:

  • Oncology
  • Neurology
  • Pharmacology

Background:

  • Peripheral neuropathy (PN) is a major complication of multiple myeloma (MM) treatment.
  • PN can arise from MM itself or therapies like bortezomib, thalidomide, vinca alkaloids, and cisplatin.
  • Up to 75% of MM patients may experience treatment-emergent PN, impacting therapeutic efficacy.

Purpose of the Study:

  • To outline the current knowledge of treatment-emergent PN in MM patients.
  • To review current management practices for PN in MM.
  • To provide recommendations for optimal PN management during MM treatment.

Main Methods:

  • Review of existing literature on PN in MM.
  • Analysis of incidence, symptoms, reversibility, and etiology of PN related to MM therapies.
  • Synthesis of current management strategies and recommendations for future research.

Main Results:

  • PN incidence and characteristics vary significantly based on MM therapies, doses, schedules, and combinations.
  • Effective PN management is critical for maintaining treatment efficacy while minimizing complication severity.
  • Early and regular neurological monitoring with potential dose modification or discontinuation is recommended.

Conclusions:

  • Optimal management of treatment-emergent PN requires a proactive approach including regular monitoring and timely intervention.
  • Further research is needed for MM-specific assessment tools, pharmacogenomics, and pharmacological interventions.
  • Balancing PN management with therapeutic efficacy is essential for improving patient outcomes in MM.

Related Concept Videos

Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...